CTI 2024 | Dr. Leo Luznik Shares Exploration and Prospects of Bone Marrow Infiltrating T Cells in the Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

CTI 2024 | Dr. Leo Luznik Shares Exploration and Prospects of Bone Marrow Infiltrating T Cells in the Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

2024.12.05
From November 14th to 17th, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was grandly held in Hangzhou, China, gathering top experts, scholars, and industry leaders in the field of global cell therapy and immune therapy. The conference served not only as an international platform for academic exchange but also as an important window to showcase the latest scientific research and promote the development of the field. During the conference, "Hematology Frontier" specially invited Dr. Leo Luznik from Baylor College of Medicine,USA to share the latest progress of Bone Marrow Infiltrating T Cells (MITs) in the treatment of relapse after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). He revealed the potential and challenges of MITs in treating relapse after HSCT and looked forward to the future development direction of the field.
CTI 2024 | Dr. Marion Subklewe Reveals How AdCAR-T Cells Dualistically Enhance the Safety and Precision of AML Treatment

CTI 2024 | Dr. Marion Subklewe Reveals How AdCAR-T Cells Dualistically Enhance the Safety and Precision of AML Treatment

2024.12.05
From November 14th to 17th, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was grandly held in Hangzhou, China, gathering top experts, scholars, and industry leaders in the field of global cell therapy and immune therapy. The conference served not only as an international platform for academic exchange but also as an important window to showcase the latest scientific research and promote the development of the field. During the conference, "Hematology Frontier" specially invited Dr. Marion Subklewe from the LMU University Hospital , Germany, to share with us the principles, advantages of AdCAR-T cell technology, and the future optimization direction of AML treatment.
CTI 2024 | IACH Chairman Dr. Mohamad Mohty: Updates on the Latest Treatment Advances in GVHD

CTI 2024 | IACH Chairman Dr. Mohamad Mohty: Updates on the Latest Treatment Advances in GVHD

2024.12.05
From November 14th to 17th, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was grandly held in Hangzhou, China, gathering top experts, scholars, and industry leaders in the field of global cell therapy and immune therapy. The conference served not only as an international platform for academic exchange but also as an important window to showcase the latest scientific research and promote the development of the field. During this conference, "Hematology Frontier" specially invited the conference chair and the chairman of the International Academy for Clinical Hematology (IACH), Dr. Mohamad Mohty from Sorbonne University , France, to share his insights on the latest treatment advances in Graft-Versus-Host Disease (GVHD), aiming to provide valuable insights for clinicians and researchers and to explore the future direction of GVHD treatment.
ASH 2024 | Dr. He Huang’s Team Secures 8 Oral Presentations, Showcasing Chinese Excellence on the Global Stage

ASH 2024 | Dr. He Huang’s Team Secures 8 Oral Presentations, Showcasing Chinese Excellence on the Global Stage

2024.12.04
The highly anticipated 66th Annual Meeting of the American Society of Hematology (ASH) will take place in San Diego, USA, from December 7 to 10, 2024. Renowned as one of the largest and most comprehensive international academic events in hematology, the ASH Annual Meeting serves as a premier platform for advancing the frontiers of the discipline. This global gathering attracts thousands of experts and scholars who come together to exchange cutting-edge research and breakthroughs in the field.
Dr. Yishan Ye on Donor Selection Trends: Insights from China’s Allogeneic Hematopoietic Stem Cell Transplantation Practice and the EBMT-China

Dr. Yishan Ye on Donor Selection Trends: Insights from China’s Allogeneic Hematopoietic Stem Cell Transplantation Practice and the EBMT-China

2024.12.04
From November 14 to 17, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was held in Hangzhou, China, attracting leading experts, scholars, and industry leaders in cellular and immune therapies. This international platform not only fosters academic exchange but also showcases the latest research breakthroughs and drives progress in the field. During the conference, Dr. Yishan Ye from The First Affiliated Hospital of Zhejiang University School of Medicine shared his insights in an interview with Hematology Frontier. He discussed the principles of donor selection in allogeneic hematopoietic stem cell transplantation (allo-HCT) and the findings from the EBMT-China collaboration. Here is the interview in full.
CTI 2024 | Professor Li Tang: Promising Horizons for CAR-T and mRNA Gene Therapy

CTI 2024 | Professor Li Tang: Promising Horizons for CAR-T and mRNA Gene Therapy

2024.12.04
From November 14 to 17, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) took place in Hangzhou, China. This global event brought together leading experts, scholars, and industry pioneers in cellular and immune therapies, serving as both an academic platform and a showcase for the latest research breakthroughs. During the conference, Hematology Frontier launched the special column “Professor, Please Answer,” featuring on-the-spot interviews with prominent professors to capture their insights and visions for the future of the field. In this edition, we share the inspiring perspectives of Professor Li Tang from École Polytechnique Fédérale de Lausanne (EPFL), Switzerland.